Expandable drug delivery devices and methods of use
First Claim
1. A drug delivery device configured to be at least partially implanted in an eye, the device comprising:
- a retention structure positioned near a proximal end region of the device;
a penetrable element coupled to and extending within at least a portion of the retention structure;
a porous drug release element positioned in fluid communication with an outlet of the device;
an elongated core element having a longitudinal axis; and
a reservoir positioned around the elongated core element, the reservoir having a volume configured to contain one or more therapeutic agents and to be in fluid communication with the outlet through the porous drug release element,wherein the device is configured to be at least partially inserted into the eye, andwherein the reservoir is configured to enlarge from an insertion configuration having a first three-dimensional shape to a deployed configuration having a second three-dimensional shape, wherein the second three-dimensional shape is eccentrically positioned relative to the longitudinal axis of the elongated core element, and wherein a first portion of the volume of the reservoir in the deployed configuration unfolds away from the lens of the eye and is greater than a remaining portion of the volume.
1 Assignment
0 Petitions
Accused Products
Abstract
Described are implantable devices having expandable reservoirs for the sustained release of therapeutic agents. The device is configured to be at least partially implanted in an eye and includes a retention structure and a penetrable element coupled to and extending within at least a portion of the retention structure. A porous drug release mechanism is positioned in fluid communication with an outlet of the device; and a reservoir having a volume configured to contain one or more therapeutic agents is in fluid communication with the outlet through the porous drug release mechanism. The device is at least partially inserted along an axis of insertion. The reservoir enlarges from an insertion configuration having a first three-dimensional shape to an expanded configuration having a second three-dimensional shape, the second three-dimensional shape being eccentrically positioned relative to the axis of insertion.
-
Citations
46 Claims
-
1. A drug delivery device configured to be at least partially implanted in an eye, the device comprising:
-
a retention structure positioned near a proximal end region of the device; a penetrable element coupled to and extending within at least a portion of the retention structure; a porous drug release element positioned in fluid communication with an outlet of the device; an elongated core element having a longitudinal axis; and a reservoir positioned around the elongated core element, the reservoir having a volume configured to contain one or more therapeutic agents and to be in fluid communication with the outlet through the porous drug release element, wherein the device is configured to be at least partially inserted into the eye, and wherein the reservoir is configured to enlarge from an insertion configuration having a first three-dimensional shape to a deployed configuration having a second three-dimensional shape, wherein the second three-dimensional shape is eccentrically positioned relative to the longitudinal axis of the elongated core element, and wherein a first portion of the volume of the reservoir in the deployed configuration unfolds away from the lens of the eye and is greater than a remaining portion of the volume. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)
-
-
25. A drug delivery device, the device comprising:
-
a proximal end region of the device comprising a retention structure and a penetrable element coupled to and extending within at least a portion of the retention structure; and a distal end region of the device configured to be at least partially implanted into an eye, the distal end region comprising; a porous drug release element positioned in fluid communication with an outlet of the device; an elongated core element; and a reservoir positioned around the elongated core element, the reservoir having a volume configured to contain one or more therapeutic agents and to be in fluid communication with the outlet through the porous drug release element, wherein the reservoir is configured to enlarge from an insertion configuration to a deployed configuration, wherein after at least partial implantation in the eye along an axis of insertion, a wall of the reservoir is configured to unfold asymmetrically relative to the elongated core element towards the deployed configuration. - View Dependent Claims (26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)
-
-
39. A drug delivery device configured to be at least partially implanted in an eye, the device comprising:
-
a reservoir formed of non-compliant material, the reservoir forming a volume configured to contain one or more therapeutic agents; an elongated core element extending through the volume between a proximal end region of the reservoir and a distal end region of the reservoir, the elongated core element having a wall surrounding a lumen, an inlet to the lumen, an outlet from the lumen, and one or more openings extending through the wall of the elongated core element between the inlet and the outlet, wherein the lumen is in fluid communication with the volume of the reservoir via the one or more openings; and a porous drug release element positioned within the outlet and configured to release the one or more therapeutic agents from the volume through the porous drug release element, wherein the non-compliant material of the reservoir is configured to collapse around the elongated core element forming a first three-dimensional shape prior to filling the volume with the one or more therapeutic agents when the device is in an insertion configuration, and wherein the non-compliant material of the reservoir is configured to eccentrically enlarge away from the elongated core element to form a second three-dimensional shape upon filling the volume with the one or more therapeutic agents when the device is in a deployed configuration. - View Dependent Claims (40, 41, 42, 43, 44, 45, 46)
-
Specification